Woodline Partners’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-671,623
| Closed | -$48.4M | – | 1139 |
|
|
2025
Q4 | $48.4M | Buy |
671,623
+347,849
| +107% | +$22.5M | 0.19% | 139 |
|
|
2025
Q3 | $14.1M | Sell |
323,774
-311,320
| -49% | -$12.6M | 0.07% | 351 |
|
|
2025
Q2 | $18M | Sell |
635,094
-230,831
| -27% | -$6.88M | 0.1% | 310 |
|
|
2025
Q1 | $25.6M | Buy |
865,925
+105
| +0% | +$3.27K | 0.17% | 180 |
|
|
2024
Q4 | $25.2M | Buy |
865,820
+187,666
| +28% | +$7.84M | 0.17% | 173 |
|
|
2024
Q3 | $31.1M | Buy |
678,154
+32,496
| +5% | +$1.41M | 0.26% | 125 |
|
|
2024
Q2 | $26.4M | Buy |
645,658
+59,320
| +10% | +$1.7M | 0.25% | 126 |
|
|
2024
Q1 | $15M | Buy |
586,338
+528,217
| +909% | +$8.28M | 0.14% | 204 |
|
|
2023
Q4 | $526K | Hold |
58,121
| – | – | 0.01% | 426 |
|
|
2023
Q3 | $371K | Hold |
58,121
| – | – | ﹤0.01% | 521 |
|
|
2023
Q2 | $645K | Hold |
58,121
| – | – | 0.01% | 518 |
|
|
2023
Q1 | $892K | Hold |
58,121
| – | – | 0.01% | 481 |
|
|
2022
Q4 | $1.29M | Buy |
58,121
+20,033
| +53% | +$299K | 0.02% | 522 |
|
|
2022
Q3 | $622K | Buy |
+38,088
| New | +$729K | 0.01% | 578 |
|
|
2022
Q1 | – | Sell |
-128,000
| Closed | -$3.04M | – | 806 |
|
|
2021
Q4 | $3.04M | Hold |
128,000
| – | – | 0.04% | 354 |
|
|
2021
Q3 | $3.15M | Hold |
128,000
| – | – | 0.05% | 330 |
|
|
2021
Q2 | $3.16M | Hold |
128,000
| – | – | 0.06% | 286 |
|
|
2021
Q1 | $2.79M | Hold |
128,000
| – | – | 0.06% | 251 |
|
|
2020
Q4 | $3.27M | Sell |
128,000
-44,978
| -26% | -$1.31M | 0.09% | 176 |
|
|
2020
Q3 | $4.87M | Buy |
172,978
+47,978
| +38% | +$1.39M | 0.16% | 131 |
|
|
2020
Q2 | $3.53M | Buy |
+125,000
| New | +$3.6M | 0.14% | 124 |
|
Other funds holding RNAM
Woodline Partners's RNAM Position: Q1 2026 in Review
Woodline Partners sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 671,623 shares — an estimated $48.4M sold.
Woodline Partners first reported a position in RNAM in Q2 2020 and held it in 21 quarters. The position peaked at $48.4M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Woodline Partners reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Woodline Partners sold 671,623 Avidity Biosciences shares in Q1 2026, an estimated $48.4M.
- Woodline Partners first reported a position in Avidity Biosciences in Q2 2020 and held it in 21 quarters.
- Woodline Partners's Avidity Biosciences position peaked at $48.4M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.